Repligen Co. (NASDAQ:RGEN) Shares Sold by Gotham Asset Management LLC

Gotham Asset Management LLC reduced its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 78.5% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 6,702 shares of the biotechnology company's stock after selling 24,539 shares during the period. Gotham Asset Management LLC's holdings in Repligen were worth $965,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of RGEN. Ballentine Partners LLC raised its position in Repligen by 4.0% during the 4th quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company's stock valued at $270,000 after purchasing an additional 72 shares in the last quarter. CIBC Asset Management Inc raised its position in Repligen by 5.0% during the 4th quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company's stock valued at $246,000 after purchasing an additional 81 shares in the last quarter. Louisiana State Employees Retirement System raised its position in Repligen by 0.7% during the 4th quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company's stock valued at $2,087,000 after purchasing an additional 100 shares in the last quarter. Utah Retirement Systems raised its position in shares of Repligen by 1.1% in the 4th quarter. Utah Retirement Systems now owns 9,294 shares of the biotechnology company's stock worth $1,338,000 after acquiring an additional 100 shares in the last quarter. Finally, Peapack Gladstone Financial Corp raised its position in shares of Repligen by 5.2% in the 4th quarter. Peapack Gladstone Financial Corp now owns 2,089 shares of the biotechnology company's stock worth $301,000 after acquiring an additional 103 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Royal Bank of Canada reduced their price target on Repligen from $202.00 to $189.00 and set an "outperform" rating for the company in a research report on Wednesday, April 30th. Wolfe Research raised Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price target for the company in a research report on Tuesday, April 29th. TD Cowen assumed coverage on Repligen in a research report on Monday, February 10th. They issued a "buy" rating and a $200.00 price target for the company. HC Wainwright reissued a "buy" rating and issued a $180.00 price target on shares of Repligen in a research report on Monday, May 5th. Finally, Canaccord Genuity Group reduced their price target on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research report on Wednesday, April 16th. Six research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, Repligen presently has an average rating of "Moderate Buy" and an average price target of $173.25.

Insider Activity

In other news, Director Margaret Pax acquired 250 shares of the business's stock in a transaction dated Monday, March 17th. The shares were acquired at an average cost of $150.69 per share, with a total value of $37,672.50. Following the completion of the acquisition, the director now owns 1,043 shares of the company's stock, valued at approximately $157,169.67. This trade represents a 31.53% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 1.20% of the company's stock.

Repligen Stock Down 5.8%

RGEN stock traded down $7.38 on Wednesday, hitting $120.21. 497,516 shares of the company's stock were exchanged, compared to its average volume of 736,442. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The firm has a 50 day moving average price of $132.06 and a two-hundred day moving average price of $144.99. The stock has a market cap of $6.75 billion, a P/E ratio of -235.71, a price-to-earnings-growth ratio of 4.54 and a beta of 1.21. Repligen Co. has a 12-month low of $102.97 and a 12-month high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, beating analysts' consensus estimates of $0.35 by $0.04. The business had revenue of $169.17 million for the quarter, compared to analyst estimates of $163.65 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The company's revenue was up 10.4% on a year-over-year basis. During the same period in the prior year, the company earned $0.28 earnings per share. As a group, equities research analysts expect that Repligen Co. will post 1.72 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.